Q3 Earnings Forecast for KROS Issued By Wedbush

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities researchers at Wedbush issued their Q3 2024 earnings per share estimates for shares of Keros Therapeutics in a research note issued to investors on Monday, November 4th. Wedbush analyst Y. Zhong expects that the company will post earnings of ($1.31) per share for the quarter. Wedbush has a “Strong-Buy” rating on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.90) per share. Wedbush also issued estimates for Keros Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. During the same quarter in the previous year, the company posted ($1.27) earnings per share.

A number of other analysts also recently issued reports on the company. Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 target price on the stock. Guggenheim began coverage on Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 price target on the stock. Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Cantor Fitzgerald started coverage on shares of Keros Therapeutics in a report on Thursday, October 24th. They set an “overweight” rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $89.11.

Keros Therapeutics Trading Up 6.2 %

Shares of KROS stock opened at $66.45 on Thursday. The firm’s fifty day moving average price is $56.87 and its two-hundred day moving average price is $51.89. Keros Therapeutics has a 1 year low of $27.31 and a 1 year high of $73.00.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KROS. Redmile Group LLC bought a new position in Keros Therapeutics during the first quarter worth about $36,576,000. Darwin Global Management Ltd. increased its holdings in shares of Keros Therapeutics by 35.4% during the first quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock worth $95,060,000 after purchasing an additional 375,523 shares during the period. Assenagon Asset Management S.A. raised its position in shares of Keros Therapeutics by 814.6% in the third quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company’s stock valued at $12,990,000 after buying an additional 199,245 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock valued at $80,666,000 after buying an additional 176,803 shares during the period. Finally, Emerald Advisers LLC acquired a new stake in Keros Therapeutics during the third quarter worth approximately $9,032,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 22.90% of the stock is currently owned by corporate insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.